PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia
Abstract
Purpose: The tumor suppressor PTEN gene and the PIK3CA oncogene are frequently mutated in uterine endometrioid carcinoma (UEC). PTEN mutations are also common in complex atypical hyperplasia (CAH), the precursor lesion of UEC. The status of PIK3CA has not yet been explored in CAH. In this study, we evaluated both CAH and UEC for PTEN and PIK3CA mutations. Experimental Design: Neoplastic tissue was microdissected, and DNA was extracted from 29 cases of CAH. DNA was available from 44 UEC cases previously characterized for PTEN mutations. Direct DNA sequencing of exons 9 and 20 of the PIK3CA gene was done on all 73 cases. In addition, CAH cases were analyzed for PTEN mutations. Statistical analyses were done using the Fisher's exact test. Results: Two (7%) of 29 CAH and 17 (39%) of 44 UEC cases contained a PIK3CA mutation (P = 0.003). Fourteen (48%) of 29 CAH cases had a PTEN mutation, but none contained both a PTEN and PIK3CA mutation. Twenty-five (57%) of 44 UEC cases had a PTEN mutation, and 12 (48%) of these 25 cases also contained a PIK3CA mutation. Coexistent PIK3CA and PTEN mutations were significantly correlated with UEC compared with CAH (P = 0.002), but the association in UEC did not reach statistical significance (P = 0.21). Conclusions: PIK3CA is the most commonly mutated oncogene in UEC; however, mutations are uncommon in CAH. Thus, mutations in PIK3CA, unlike PTEN mutations, are associated with invasion. These findings suggest that mutations in PIK3CA may serve as a marker of invasion with potential clinical use. Furthermore, PIK3CA and PTEN mutations may play distinct roles in endometrial tumorigenesis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This hypothesis had never before been tested in an isogenic model.
“While this hypothesis has been previously proposed48,50–52, it had never before been tested in an isogenic model.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [50]
This overcame a major bottleneck to successfully model early endometrial tumorigenesis.
“thereby overcoming a major bottleneck to successfully model early endometrial tumorigenesis50.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [50]
The toolkit has a significant advantage to generate isogenic models of novel mutations in early tumorigenesis.
“Taken together, these results demonstrate the significant advantage the toolkit we have developed in this study has to generate isogenic models of novel mutations in early tumorigenesis48,50–52.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [50]
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works
Jemal, A., Siegel, R. L., Ward, E. M., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,309 · see citing works
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R. A., Godfrey, T. E., Collins, C. C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,158 · see citing works
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 917 · see citing works
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915 · see citing works
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 827 · see citing works
Tashiro, H., Blazes, M. S., Wu, R., Cho, K. R., Bose, S., Wang, S. I., Li, J., Parsons, R. E., & Ellenson, L. H. (1997) · PubMed · Cited by 701 · see citing works
Self-citationTrimble, C. L., Kauderer, J. T., Zaino, R. J., Silverberg, S., Lim, P., Burke, J. J., Alberts, D. S., & Curtin, J. P. (2006) · Cancer · doi:10.1002/cncr.21650 · Cited by 603 · see citing works
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 505 · see citing works
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 467 · see citing works
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 423 · see citing works
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 421 · see citing works
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4114 · Cited by 366 · see citing works
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324 · see citing works
Levine, R. L., Cargile, C. B., Blazes, M. S., van Rees, B. P., Kurman, R. J., & Ellenson, L. H. (1998) · PubMed · Cited by 290 · see citing works
Self-citationKendall, B. S., Ronnett, B. M., Isacson, C., Cho, K. R., Hedrick, L., Diener‐West, M., & Kurman, R. J. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199808000-00012 · Cited by 253 · see citing works
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Maxwell, G. L., Risinger, J. I., Gumbs, C. E., Shaw, H., Bentley, R. C., Barrett, J. C., Berchuck, A., & Futreal, P. A. (1998) · PubMed · Cited by 231 · see citing works
K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto, T., Inoue, M., Perantoni, A. O., Buzard, G. S., Miki, H., Tanizawa, O., & Rice, J. M. (1991) · PubMed · Cited by 156 · see citing works
Risk of familial breast cancer
Anderson, D. E., & Badzioch, M. D. (1985) · Cancer · doi:10.1002/1097-0142(19850715)56:2 · Cited by 113 · see citing works
Mutter, G. L., Wada, H., Faquin, W. C., & Enomoto, T. (1999) · Molecular Pathology · doi:10.1136/mp.52.5.257 · Cited by 61 · see citing works
Molecular genetic characterization of tamoxifen-associated endometrial cancer
Prasad, M., Wang, H., Douglas, W., Barakat, R. R., & Ellenson, L. H. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.046 · Cited by 32 · see citing works
Self-citationWajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Crosbie, E. J., Kitson, S., McAlpine, J. N., Mukhopadhyay, A., Powell, M. E., & Singh, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00323-3 · Cited by 1,401 · see citing works
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245 · see citing works
Self-citationMolecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765 · see citing works
Classification of endometrial carcinoma: more than two types
Murali, R., Soslow, R. A., & Weigelt, B. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70591-6 · Cited by 649 · see citing works
Jankú, F., Wheler, J. J., Westin, S. N., Moulder, S., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido‐Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 448 · see citing works
Molecular Genetics of Endometrial Carcinoma
Bell, D. W., & Ellenson, L. H. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043609 · Cited by 299 · see citing works
Self-citationOncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291 · see citing works
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Press, J. Z., Luca, A. D., Boyd, N., Young, S. S., Troussard, A. A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M. J., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287 · see citing works
Slomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M. F., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 270 · see citing works
Yamamoto, S., Tsuda, H., Takano, M., Tamai, S., & Matsubara, O. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.189 · Cited by 259 · see citing works
Therapeutic options for management of endometrial hyperplasia
Chandra, V., Kim, J.-J., Benbrook, D. M., Dwivedi, A., & Rai, R. (2015) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e8 · Cited by 224 · see citing works
PTEN signaling in brain: neuropathology and tumorigenesis
Endersby, R., & Baker, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.239 · Cited by 222 · see citing works
Self-citationTargeting the PI3K signaling pathway in cancer therapy
Bartholomeusz, C., & Gonzalez-Angulo, A. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.644788 · Cited by 218 · see citing works
Gibson, W. J., Høivik, E. A., Halle, M. K., Taylor-Weiner, A. N., Cherniack, A. D., Berg, A., Holst, F., Zack, T. I., Werner, H. M. J., Staby, K. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3602 · Cited by 208 · see citing works
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Jankú, F., Lee, J. J., Tsimberidou, A. M., Hong, D. S., Naing, A., Falchook, G. S., Fu, S., Luthra, R., Garrido‐Laguna, I., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022769 · Cited by 203 · see citing works
Oda, K., Okada, J., Timmerman, L., Rodriguez‐Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0755 · Cited by 189 · see citing works
Djordjevic, B., Hennessy, B. T., Li, J., Barkoh, B. A., Luthra, R., Mills, G. B., & Broaddus, R. R. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.208 · Cited by 175 · see citing works
Ellenson, L. H., & Pirog, E. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50027-4 · Cited by 171 · see citing works
Self-citationHong, D. S., Bowles, D. W., Falchook, G. S., Messersmith, W. A., George, G. C., O’Bryant, C. L., Vo, A. C. H., Klucher, K. M., Herbst, R. S., Eckhardt, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0714 · Cited by 169 · see citing works
Efficient Use of Patient-Derived Organoids as a Preclinical Model for Gynecologic Tumors
Maru, Y., Tanaka, N., Itami, M., & Hippo, Y. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.005 · Cited by 162 · see citing works
Llobet‐Navàs, D., Pallarés, J., Yeramian, A., Santacana, M., Eritja, N., Velasco, A., Dolcet, X., & Matías‐Guiu, X. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.056101 · Cited by 155 · see citing works
Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development
Jones, A., Teschendorff, A. E., Li, Q., Hayward, J. D., Kannan, A., Mould, T., West, J., Zikán, M., Cibula, D., Fiegl, H., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001551 · Cited by 150 · see citing works
Cancer-specific mutations in phosphatidylinositol 3-kinase
Vogt, P. K., Kang, S., Elsliger, M., & Gymnopoulos, M. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.05.005 · Cited by 144 · see citing works
Oncogenic mutations in histologically normal endometrium: the new normal?
Lac, V., Nazeran, T. M., Tessier‐Cloutier, B., Aguirre-Hernández, R., Albert, A., Lum, A. M., Khattra, J. S., Praetorius, T., Mason, M., Chiu, D. S., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5314 · Cited by 139 · see citing works
Subtype‐specific mutation of PPP2R1A in endometrial and ovarian carcinomas
McConechy, M. K., Anglesio, M. S., Kalloger, S. E., Yang, W., Senz, J., Chow, C., Heravi‐Moussavi, A., Morin, G. B., Mes‐Masson, A., Chenevix‐Trench, G., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2848 · Cited by 131 · see citing works
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma
Koul, D., Shen, R., Kim, Y., Kondo, Y., Lu, Y., Bankson, J. A., Ronen, S. M., Kirkpatrick, D. L., Powis, G., & Yung, W. K. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop058 · Cited by 128 · see citing works
Catasús, L., Gallardo, A., Cuatrecasas, M., & Prat, J. (2007) · Modern Pathology · doi:10.1038/modpathol.3800992 · Cited by 126 · see citing works
The genomics and genetics of endometrial cancer
Bell, D. W., & Ohara (2012) · Advances in Genomics and Genetics · doi:10.2147/agg.s28953 · Cited by 126 · see citing works
Colombo, N., McMeekin, D. S., Schwartz, P. E., Sessa, C., Gehrig, P. A., Holloway, R. W., Braly, P. S., Matei, D. E., Morosky, A., Dodion, P. F., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.59 · Cited by 124 · see citing works
Gargiulo, P., Pepa, C. D., Berardi, S., Califano, D., Scala, S., Buonaguro, L., Ciliberto, G., Brauchli, P., & Pignata, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.008 · Cited by 125 · see citing works
Catasús, L., Gallardo, A., Cuatrecasas, M., & Prat, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.5 · Cited by 122 · see citing works
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
Dunlap, J. B., Le, C., Shukla, A., Patterson, J., Presnell, A., Heinrich, M. C., Corless, C. L., & Troxell, M. L. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0406-1 · Cited by 121 · see citing works
McIntyre, J. B., Wu, J. S.-Y., Craighead, P. S., Phan, T., Köbel, M., Lees‐Miller, S. P., Ghatage, P., Magliocco, A. M., & Doll, C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.019 · Cited by 117 · see citing works
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors
Lin, Y. Q., Jiang, X., Shen, Y., Li, M., Ma, H., Xing, M., & Lu, Y. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0167 · Cited by 110 · see citing works
Ray-Coquard, I., Favier, L., Weber, B. E., Roemer-Bécuwe, C., Bougnoux, P., Fabbro, M., Floquet, A., Joly, F., Plantade, A., Paraiso, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.183 · Cited by 106 · see citing works
McDonald, M. E., & Bender, D. (2019) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2018.09.006 · Cited by 106 · see citing works
Yamamoto, S., Tsuda, H., Takano, M., Tamai, S., & Matsubara, O. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1169-8 · Cited by 99 · see citing works
Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas
Helbig, D., Ihle, M. A., Pütz, K., Tantcheva‐Poór, I., Mauch, C., Büttner, R., & Quaas, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7845 · Cited by 99 · see citing works
Jimeno, A., Shirai, K., Choi, M., Laskin, J. J., Kochenderfer, M. D., Spira, A. I., Cline-Burkhardt, V. J. M., Winquist, E., Hausman, D. F., Walker, L. N., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu574 · Cited by 99 · see citing works
Genomic landscape of endometrial carcinomas of no specific molecular profile
Boroujeni, A. M., Nguyen, B., Vanderbilt, C., Ladanyi, M., Abu‐Rustum, N. R., Aghajanian, C. A., Ellenson, L. H., Weigelt, B., & Soslow, R. A. (2022) · Modern Pathology · doi:10.1038/s41379-022-01066-y · Cited by 98 · see citing works
Self-citationPrecursor Lesions of Endometrial Carcinoma
Ellenson, L. H., Ronnett, B. M., & Kurman, R. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0489-8_8 · Cited by 94 · see citing works
Self-citationMakker, A., & Goel, M. M. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0218 · Cited by 91 · see citing works
Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences
Felix, A. S., Yang, H., Bell, D. W., & Sherman, M. E. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_1 · Cited by 90 · see citing works
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
Tsoref, D., Welch, S. A., Lau, S. K., Biagi, J. J., Tonkin, K. S., Martin, L. A., Ellard, S. L., Ghatage, P., Elit, L. M., MacKay, H. J., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.033 · Cited by 89 · see citing works
Structural Determinants of Isoform Selectivity in PI3K Inhibitors
Miller, M. S., Thompson, P. E., & Gabelli, S. B. (2019) · Biomolecules · doi:10.3390/biom9030082 · Cited by 89 · see citing works
Multiplex Mutation Screening by Mass Spectrometry
Beadling, C., Heinrich, M. C., Warrick, A., Forbes, E. M., Nelson, D., Justusson, E., Levine, J., Neff, T. L., Patterson, J., Presnell, A., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.04.003 · Cited by 81 · see citing works
The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer
Diver, E., Foster, R., Rueda, B. R., & Growdon, W. B. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0149 · Cited by 82 · see citing works
Jimeno, A., Bauman, J. E., Weissman, C., Adkins, D. R., Schnadig, I. D., Beauregard, P., Bowles, D. W., Spira, A. I., Levy, B. P., Seetharamu, N., et al. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.12.013 · Cited by 78 · see citing works
MacKay, H. J., Eisenhauer, E. A., Kamel‐Reid, S., Tsao, M., Clarke, B. A., Karakasis, K., Werner, H. M. J., Trovik, J., Akslen, L. A., Salvesen, H. B., et al. (2013) · Cancer · doi:10.1002/cncr.28414 · Cited by 75 · see citing works
Rubinstein, M. M. Z., Hyman, D. M., Caird, I., Won, H. H., Soldan, K., Seier, K., Iasonos, A. E., Tew, W. P., O'Cearbhaill, R. E., Grisham, R. N., et al. (2019) · Cancer · doi:10.1002/cncr.32677 · Cited by 74 · see citing works
Wang, Y., Yin, L., & Sun, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01679-8 · Cited by 74 · see citing works
Sarmadi, S., Izadi‐Mood, N., Sotoudeh, K., & Tavangar, S. M. (2009) · Diagnostic Pathology · doi:10.1186/1746-1596-4-41 · Cited by 71 · see citing works
Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Chen, J., Zhao, K., Li, R., Shao, R., & Chen, C. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140414095605 · Cited by 71 · see citing works
One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids
Geurts, M. H., Gandhi, S., Boretto, M. G., Akkerman, N., Derks, L. L. M., van Son, G., Celotti, M., Harshuk-Shabso, S., Peci, F., Begthel, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40701-3 · Cited by 66 · see citing works
“5c – e), thereby overcoming a major bottleneck to successfully model early endometrial tumorigenesis 50 .”
Wild, P. J., Ikenberg, K., Fuchs, T. J., Rechsteiner, M., Georgiev, S., Fankhauser, N., Noske, A., Roessle, M., Caduff, R. F., Dellas, A., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101063 · Cited by 66 · see citing works
Personalized therapy in endometrial cancer: Challenges and opportunities
Westin, S. N., & Broaddus, R. R. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.1.18438 · Cited by 66 · see citing works
Fountzilas, G., Bobos, M., Kalogera‐Fountzila, A., Xiros, N., Murray, S. J., Linardou, H., Karayannopoulou, G., Koutras, A. K., Bafaloukos, D. I., Samantas, E., et al. (2008) · Cancer Investigation · doi:10.1080/07357900801918611 · Cited by 65 · see citing works
Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas
Jones, N., Xiu, J., Chatterjee‐Paer, S., de Meritens, A. B., Burke, W. M., Tergas, A. I., Wright, J. D., & Hou, J. Y. (2016) · International Journal of Cancer · doi:10.1002/ijc.30537 · Cited by 63 · see citing works
Bowles, D. W., Ma, W. W., Senzer, N. N., Brahmer, J. R., Adjei, A. A., Davies, M. A., Lazar, A. J., Vo, A. C. H., Peterson, S., Walker, L. N., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.474 · Cited by 62 · see citing works
High‐grade endometrial carcinomas – strategies for typing
Soslow, R. A. (2012) · Histopathology · doi:10.1111/his.12029 · Cited by 62 · see citing works
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma
Ollikainen, M., Gylling, A., Puputti, M., Nupponen, N. N., Abdel‐Rahman, W. M., Bützow, R. C., & Peltomäki, P. (2007) · International Journal of Cancer · doi:10.1002/ijc.22768 · Cited by 62 · see citing works
Cheng, H.-L. M., Liu, P., Zhang, F., Xu, E., Symonds, L. K., Ohlson, C. E., Bronson, R. T., Maira, S.-M., di Tomaso, E., Li, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0544 · Cited by 61 · see citing works
Molecular targets and targeted therapeutics in endometrial cancer
Weigelt, B., & Banerjee, S. N. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328354e585 · Cited by 60 · see citing works
PPP2R1A mutations are common in the serous type of endometrial cancer
Nagendra, D., Burke, J. J., Maxwell, G. L., & Risinger, J. I. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20850 · Cited by 59 · see citing works
Lauring, J. D., Cosgrove, D., Fontana, S. C., Gustin, J. P., Konishi, H., Abukhdeir, A. M., Garay, J. P., Mohseni, M., Wang, G., Higgins, M. J., et al. (2010) · Oncogene · doi:10.1038/onc.2009.516 · Cited by 59 · see citing works
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma
Cohen, Y., Shalmon, B., Korach, J., Barshack, I., Fridman, E., & Rechavi, G. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.038 · Cited by 58 · see citing works
Wang, L., Ma, H., Stemke‐Hale, K., Yin, M., Meyer, L. A., Liu, H., Li, J., Lu, K. H., Hennessy, B. T., Li, X., et al. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1103-0 · Cited by 58 · see citing works
Molecular characterization of endometrial cancer and therapeutic implications
Winterhoff, B. J. N., Thomaier, L., Mullany, S. A., & Powell, M. A. (2019) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000602 · Cited by 59 · see citing works
Recent Advances in Endometrial Cancer
Tran, A.-Q., & Gehrig, P. A. (2017) · F1000Research · doi:10.12688/f1000research.10020.1 · Cited by 57 · see citing works
Molecular characterization of endometrial cancer and therapeutic implications
Chang, Z., Talukdar, S., Mullany, S. A., & Winterhoff, B. J. N. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000508 · Cited by 57 · see citing works
Konopka, B., Janiec–Jankowska, A., Kwiatkowska, E., Najmoła, U., Bidziński, M., Olszewski, W. T., & Goluda, C. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.01.030 · Cited by 57 · see citing works
Ellagic acid exerts antitumor effects via the PI3K signaling pathway in endometrial cancer
Wang, Y., Ren, F., Li, B., Song, Z., Chen, P., & Ouyang, L. (2019) · Journal of Cancer · doi:10.7150/jca.29738 · Cited by 57 · see citing works
The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis
Delangle, R., de Foucher, T., Larsen, A. K., Sabbah, M., Azaïs, H., Bendifallah, S., Daraï, É., Ballester, M., Méhats, C., Uzan, C., et al. (2019) · Cancers · doi:10.3390/cancers11060832 · Cited by 57 · see citing works
Tanos, P., Dimitriou, S., Gullo, G., & Tanos, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052653 · Cited by 56 · see citing works
Berg, A., Høivik, E. A., Mjøs, S., Holst, F., Werner, H. M. J., Tangen, I. L., Taylor-Weiner, A. N., Gibson, W. J., Kusonmano, K., Wik, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2675 · Cited by 56 · see citing works
Endometrial Carcinoma: Specific Targeted Pathways
Eritja, N., Yeramian, A., Chen, B., Llobet‐Navàs, D., Ortega, E., Colás, E., Abal, M., Dolcet, X., Reventós, J., & Matías‐Guiu, X. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_6 · Cited by 58 · see citing works
Gallo, M. L., Lozy, F., & Bell, D. W. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_5 · Cited by 54 · see citing works
Conza, D., Mirra, P., Calı̀, G., Tortora, T., Insabato, L., Fiory, F., Schenone, S., Amato, R., Bèguinot, F., Perrotti, N., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25850 · Cited by 54 · see citing works
Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium
Hsu, A. H., Lum, M. A., Shim, K.-S., Frederick, P. J., Morrison, C. D., Chen, B., Lele, S. M., Sheinin, Y. M., Daikoku, T., Dey, S. K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.067 · Cited by 53 · see citing works
Eritja, N., Llobet‐Navàs, D., Domingo, M., Santacana, M., Yeramian, A., Matías‐Guiu, X., & Dolcet, X. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090974 · Cited by 51 · see citing works
Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology
Akhtar, M., Hyassat, S. A., Elaiwy, O., Rashid, S., & Al-Nabet, A. D. M. H. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000251 · Cited by 50 · see citing works
Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer
Gavgani, F. M., Arnesen, V. S., Jacobsen, R. G., Krakstad, C., Høivik, E. A., & Lewis, A. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123931 · Cited by 50 · see citing works
Castellví, J., García, Á., Ruiz-Marcellán, C., Hernández‐Losa, J., Peg, V., Salcedo, M., Gil‐Moreno, A., & y Cajal, S. R. (2009) · Human Pathology · doi:10.1016/j.humpath.2008.12.019 · Cited by 45 · see citing works
Progressive derailment of cell cycle regulators in endometrial carcinogenesis
Horrée, N., van Diest, P. J., van der Groep, P., Go, D. M. D. S., & Heintz, A. P. M. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043794 · Cited by 45 · see citing works
Wang, J., Chen, C., Wang, S., Zhang, Y., Yin, P., Gao, Z., Xu, J., Feng, D.-X., Zuo, Q., Zhao, R., et al. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/457193 · Cited by 44 · see citing works
Update on Prognostic Markers for Endometrial Cancer
Binder, P., & Mutch, D. G. (2014) · Women s Health · doi:10.2217/whe.14.13 · Cited by 43 · see citing works
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma
Kang, S., Seo, S., Chang, H. J., Yoo, C. W., Park, S. Y., & Dong, S. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01172.x · Cited by 43 · see citing works
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast
Li, H., Zhu, R., Wang, L., Zhu, T., Li, Q., Chen, Q., Wang, H., & Zhu, H. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.09.016 · Cited by 42 · see citing works
Self-citationPatel, V., Kipp, B. R., & Schoolmeester, J. K. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.08.018 · Cited by 42 · see citing works
Westin, S. N., Sill, M. W., Coleman, R. L., Waggoner, S. E., Moore, K. N., Mathews, C. A., Martin, L. P., Modesitt, S. C., Lee, S., Ju, Z., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.09.024 · Cited by 42 · see citing works
Major clinical research advances in gynecologic cancer in 2012
Suh, D. H., Kim, J., Kim, K., Kim, H. J., & Lee, K.-H. (2013) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2013.24.1.66 · Cited by 41 · see citing works
Russo, M., Broach, J. R., Sheldon, K. E., Houser, K. R., Liu, D. J., Kesterson, J. P., Phaëton, R., Hossler, C., Hempel, N., Baker, M. J., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.07.003 · Cited by 41 · see citing works
Ellenson, L. H., Ronnett, B. M., Soslow, R. A., Zaino, R. J., & Kurman, R. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0489-8_9 · Cited by 41 · see citing works
Self-citationMutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas
Murat, C. D. B., Braga, P. B., Fortes, M. A. H. Z., Bronstein, M. D., Corrêa‐Giannella, M. L., & Giorgi, R. R. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500115 · Cited by 41 · see citing works
Zhang, X., Zhang, H.-Y., Zhang, P., Lü, X., & Sun, H. (2008) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2007.12.021 · Cited by 40 · see citing works
Risinger, J. I., Allard, J. E., Chandran, U. R., Day, R., Chandramouli, G. V. R., Miller, C. R., Zahn, C. M., Oliver, J., Litzi, T. A., Marcus, C. S., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00139 · Cited by 39 · see citing works
Molecular profiles of benign and (pre)malignant endometrial lesions
van der Putten, L. J. M., van Hoof, R., Tops, B. B. J., Snijders, M. P. L. M., Erp, S. V. D. B.-V., van der Wurff, A. A. M., Bulten, J., Pijnenborg, J. M. A., & Massuger, L. F. A. G. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx008 · Cited by 39 · see citing works
Wang, Y., Yu, M. Y., Yang, J., Cao, D., Zhang, Y., Zhou, H., Yuan, Z., & Shen, K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00123 · Cited by 39 · see citing works
Protein kinase C alpha‐dependent signaling mediates endometrial cancer cell growth and tumorigenesis
Haughian, J. M., Reno, E. M., Thorne, A. M., & Bradford, A. P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24633 · Cited by 36 · see citing works
Molecular alterations in uterine serous carcinoma
Hayes, M. P., & Ellenson, L. H. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.11.012 · Cited by 34 · see citing works
Self-citation
- Authors
- Hayes, M. P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G. J., Baker, S. J., & Ellenson, L. H.
- Affiliations
- Cornell University (US)
- St. Jude Children's Research Hospital (US)
- Venue
- Clinical Cancer Research
- Published
- 2006-10-15
- Volume
- 12
- Issue
- 20
- Pages
- 5932-5935
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2101549875
- Cited by
- 218
- References
- 23
- Citations by year
- 2025: 6 · 2024: 10 · 2023: 9 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 19 · 2018: 16 · 2017: 11 · 2016: 15 · 2015: 12 · 2014: 11 · 2013: 17 · 2012: 21
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA095427, CA 095427)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- PIK3CA mutation, PTEN mutation, endometrioid endometrial cancer, complex atypical hyperplasia, endometrial tumorigenesis, tumor invasion, co-occurring mutations, precursor lesions
- MeSH terms
- DNA, Neoplasm, Endometrium, Female, Humans, Hyperplasia, Mutation, Uterine Neoplasms, Endometrial Neoplasms, Phosphatidylinositol 3-Kinases, PTEN Phosphohydrolase, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
